Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB, Houtsma D, Nortier JW, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, Putter H, Seynaeve C, Gelderblom H, van de Velde CJ, Guchelaar HJ. Fontein DB, et al. Among authors: van der straaten tr. Breast Cancer Res Treat. 2014 Apr;144(3):599-606. doi: 10.1007/s10549-014-2873-2. Epub 2014 Mar 4. Breast Cancer Res Treat. 2014. PMID: 24590773 Clinical Trial.
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, van de Velde CJ, Nortier JW, Gelderblom H, Guchelaar HJ. Dezentjé VO, et al. Breast Cancer Res Treat. 2013 Jul;140(2):363-73. doi: 10.1007/s10549-013-2619-6. Epub 2013 Jul 11. Breast Cancer Res Treat. 2013. PMID: 23842856 Clinical Trial.
Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
Charehbili A, de Groot S, van der Straaten T, Swen JJ, Pijl H, Gelderblom H, van de Velde CJ, Nortier JW, Guchelaar HJ, Kroep JR. Charehbili A, et al. Pharmacogenomics. 2015;16(11):1267-76. doi: 10.2217/PGS.15.74. Epub 2015 Aug 20. Pharmacogenomics. 2015. PMID: 26289095 Clinical Trial.
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO, Opdam FL, Gelderblom H, Hartigh den J, Van der Straaten T, Vree R, Maartense E, Smorenburg CH, Putter H, Dieudonné AS, Neven P, Van de Velde CJ, Nortier JW, Guchelaar HJ. Dezentjé VO, et al. Breast Cancer Res Treat. 2015 Oct;153(3):583-90. doi: 10.1007/s10549-015-3562-5. Epub 2015 Sep 14. Breast Cancer Res Treat. 2015. PMID: 26369533 Free PMC article.
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO, Gelderblom H, Van Schaik RH, Vletter-Bogaartz JM, Van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, Van de Velde CJ, Nortier JW, Guchelaar HJ. Dezentjé VO, et al. Breast Cancer Res Treat. 2014 Jan;143(1):171-9. doi: 10.1007/s10549-013-2777-6. Epub 2013 Nov 22. Breast Cancer Res Treat. 2014. PMID: 24265036
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. van Erp NP, et al. J Clin Oncol. 2009 Sep 10;27(26):4406-12. doi: 10.1200/JCO.2008.21.7679. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667267
77 results